Diclofenac Sodium Nanomedicine Results in Pain-relief and Differential Expression of the RNA Transcriptome in the Spinal Cord of Spared Nerve Injury Rats

Abstract

Abstract Neuropathic pain is chronic pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain, with high incidence and complex pathogenesis, is one of the hot spots in clinical medicine and basic research. Currently, prescribed treatments are still unsatisfactory or have limited effectiveness. A medicinal preparation is required that relieves the neuropathic pain and prolongs action time, which has not been discovered. In this study, MIL-101 (Fe) was used to prepare as a drug carrier to control the release of diclofenac sodium, thus achieving the effect of analgesic and sustained release. The release curves revealed that diclofenac sodium could be consecutively released from MIL-101 (Fe) for more than 48 hours. There was no toxicity in vitro and in vivo, and the safety of MIL-101 (Fe) is confirmed by hematoxylin and eosin (HE) and ELISA tests in vivo. The results of behavioral testing, pharmacokinetics, and RNA sequencing analysis showed that MIL-101 (Fe) loaded with diclofenac sodium could improve the mechanical withdrawal threshold (MWT) and cold allodynia induced by SNI, extending the work time for three days. The results indicated that MIL-101 (Fe) possessed good biocompatibility, and the MIL-101 (Fe)-DS takes on analgesic and controlled-release effects, which provides a scientific basis for the clinical treatment of neuropathic pain and the preparation of a new formulation.